Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
about
Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer CellsOrchestration of angiogenesis by immune cellsPathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerCoordinated regulation of myeloid cells by tumoursMyeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.Immunotherapeutic approaches for hepatocellular carcinomaHigher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection.Myeloid derived suppressor cells in human diseasesCross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppressionThe anergic state in sarcoidosis is associated with diminished dendritic cell function.The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion ChemotherapyDefective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease.Therapeutic implications of immunogenic cell death in human cancer.Immunobiology of hepatocellular carcinoma.Tumor associated regulatory dendritic cells.The immune network in pancreatic cancer development and progression.Dendritic cell defects in the colorectal cancerPharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives.Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform.Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.Role of lymphocytes in liver cancer.HCV core and NS3 proteins manipulate human blood-derived dendritic cell development and promote Th 17 differentiation.Dendritic cells in the cancer microenvironment.Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling
P2860
Q26752653-0FEF15DD-80F4-4DFD-A449-EF9012150981Q28389236-D570C465-5882-4EA6-AD07-33B6AC0CE5BDQ28392626-679A8FA4-7F0D-4667-9336-07033F61FBF7Q28395157-6395C0FF-EB54-4CD4-83C1-D162E58A22FAQ33474008-F48E0E6F-858E-4F8E-8BD3-54B71444ED48Q33779723-6F669BB1-B064-4744-BE41-E3EBB2FF1355Q34648541-88382D4F-0D31-4F55-A7F2-FF99072BA1B3Q35567765-F4EA5FAE-1557-4C29-8E4C-7BCFF9482F55Q36326364-8568DC6D-4581-492A-9BE0-EED9F6A3DBA6Q36338349-BF33B463-8E80-45D9-B245-5978AFFDAA96Q36983876-387647EF-DBB4-400E-BB6D-B1FD8BE19433Q36995998-D54CCF2C-6BB7-432C-BE98-A736B236BD24Q37204018-061FE147-4391-427C-A3B7-916A8276FED9Q37375412-1814AAE2-3F2D-4062-A0A8-A5ED6E10FB13Q37434072-0E4C60C1-AFEE-4335-BFD3-E80BA7774A5DQ37863516-BBD40B91-4748-4C98-AB73-C4B5AEF40246Q37993359-31495B86-8543-433C-88F7-43C38825896BQ38121412-C2B0DF0A-43AB-46D2-9453-EC0C36760C95Q38284706-D2EA7E50-06C2-49D6-81B8-B9A339FD8A27Q38853680-54BD8E57-7CD9-4E8D-AE5D-29CF63AAB6EBQ39101230-4B5B965A-89E1-4CFE-A6B5-A587A010C7D3Q39974466-CCAFD480-9C4A-4F03-8270-61B4E7A7168FQ41790593-2576D4B7-13DD-4F9D-BB51-2455BF547E80Q41874816-46DE5B64-48D2-458C-AFC8-4D05BEAB4768Q42024872-E86811E9-5A43-4143-86FA-22C4CF2141CEQ42551019-CB184A64-19FA-40D7-88DA-DE1BD2B94867Q43047372-EFF47970-F578-4835-8792-5CA3DEDE4273Q43163888-B2EC2731-626A-4029-8E43-BD1F92088A6FQ46244349-0528C997-E075-430D-AC31-017137E997BBQ57821146-E65D35C7-7C58-41D5-BB6B-EEA8665BE79C
P2860
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@ast
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@en
type
label
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@ast
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@en
prefLabel
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@ast
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@en
P2093
P2860
P356
P1476
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
@en
P2093
Anatol Farber
Firouzeh Korangy
Frank Lehner
Heiner Wedemeyer
Lars-A Ormandy
Michael-P Manns
Monique Horning
Susanne Petrykowska
Tim-F Greten
Tobias Cantz
P2860
P304
P356
10.3748/WJG.V12.I20.3275
P407
P577
2006-05-01T00:00:00Z